Publication of Coronavirus White Papers
Emergex publishes three White Papers highlighting the case for developing [...]
Emergex Raises More Than US$11 million in a Series A Round to Progress its Pipeline of Set-point Vaccines for Infectious Diseases
Emergex develops set-point vaccines to prevent some of the world’s [...]
Emergex Completes First Step in the Development of a Vaccine Candidate Against Intracellular Bacterium and Bioterrorist Agent Francisella Tularensis
Emergex today announced it has successfully completed the first step in the development of a candidate vaccine for the Gram-negative intracellular coccobacillus, Francisella tularensis.
Emergex Successfully Completes Preclinical Testing of its Lead Set-Point Vaccine Candidate for Dengue Fever and Other Flaviviruses
Emergex today announced the successful completion of preclinical testing of its lead vaccine candidate for Dengue Fever.
Emergex Signs an R&D Agreement with IMCB to Develop a Vaccine for the Emerging Threat of Hand, Foot & Mouth Disease
Emergex today announced that it has signed an R&D agreement with the Institute of Molecular and Cell Biology (IMCB) in Singapore to develop a fully synthetic vaccine against human viruses that cause Hand, Foot and Mouth Disease (HFMD). Emergex and IMCB will collaborate closely to develop the new vaccine, combining their personnel, specialist knowledge and expertise.
Dr. Athanasios Papadopoulos Joins Emergex as Chief Medical Officer
Emergex today announces the appointment of Athanasios Papadopoulos, MD, as Chief Medical Officer (CMO), effective 1st March 2019. Dr. Papadopoulos will report directly to Emergex’s CEO Professor Thomas Rademacher.
Emergex Secures State-of-the-art R&D Facility and Hires a Chief Scientific Officer to Drive Development of its Vaccines
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a novel approach to the development of vaccines for infectious diseases, today announces that it has successfully secured a state-of-the-art-research and development (R&D) facility at Milton Park, Oxfordshire.
Emergex Demonstrates Excellent Safety Profile for Gold Nanoparticle Used in its Vaccine Platform
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces the successful completion of preclinical toxicology testing on the gold nanoparticle carrier system that forms the fundamental basis for Emergex’s entire infectious disease vaccine platform.
Emergex Enters into MoU with Brazil’s Fiocruz to Develop Novel Vaccines Against Viral Diseases
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces that it has signed a Memorandum of Understanding (MoU) with Brazil-based Oswaldo Cruz Foundation ‘Fiocruz’ for the development of viral vaccines. The MoU initially covers the development of a vaccine that universally targets diseases within the flavivirus family such as Dengue Fever, Zika and Yellow Fever but could be expanded to include the development of vaccines to target other viral families that are endemic to the region.
Emergex Appoints US Federal Government Experts The Conafay Group
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that it has appointed The Conafay Group, US Federal Government experts, to advise on the US healthcare landscape and policy and to provide introductions to help establish new business contacts.